DIA 2017 Annual Meeting

Component Type: Forum
Level: Intermediate
CE: CME 1.00; IACET 1.00; RN 1.00

Emerging research points to the significant role of microbiome in contributing to disease and how promoting maintenance of a “healthy microbiome” across a wide variety of disease states can maintain health, prevent, intercept, and treat disease states. How do we handle the complexity of the microbiome in conducting clinical research and monitoring? Does addressing the microbiome impact how we view disease and clinical practice? Do we need new regulatory and medical approaches to manage?

Learning Objectives

Describe the complexity of the microbiome in both health and disease management; Identify how addressing the microbiome can fundamentally change our approach to medicine.

Chair

Caroline B. Kurtz, PhD

Speaker

Overview of the Microbiome and Approaches to Therapeutic Development
Caroline B. Kurtz, PhD

Regulatory Aspects of Microbiome Product Development
James R. Weston, MBA

Clinical Development Challenges for Microbiome Drug Development
Paul K. Plumb